Geron Corporation vs BioCryst Pharmaceuticals, Inc.: Annual Revenue Growth Compared

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, BioCryst Pharmaceuticals, Inc. and Geron Corporation have taken divergent paths. BioCryst has seen a remarkable revenue increase, growing from approximately $14 million in 2014 to over $331 million in 2023, marking a staggering 2,264% growth. This surge highlights BioCryst's strategic advancements and market adaptability.

Conversely, Geron Corporation's revenue trajectory tells a different story. Starting at around $1.15 million in 2014, Geron's revenue peaked at $36 million in 2015 but has since dwindled to $237,000 in 2023. This decline, a drop of nearly 80% from its peak, underscores the challenges Geron faces in maintaining its market position.

These contrasting trends offer a fascinating glimpse into the dynamic landscape of biotech innovation and competition.